Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Buy RNAi and Gene Therapy Company Mirus Bio for $125M

NEW YORK (GenomeWeb News) – Roche said today that it will buy RNAi technologies company Mirus Bio Corporation for $125 million.
Roche plans to divest Mirus’ transfection reagents into a stand-alone business called Mirus Bio LLC, and it expects to offer employees of the Madison, Wis.-based company a transition into respective business units. The Swiss firm intends to retain an RNAi research site at the facilities in Madison.
Roche said that it expects to complete the transaction during the second half of 2008.
Mirus Bio is involved in RNAi and gene therapy, with products for siRNA therapeutics, one of which is a treatment for muscular dystrophy that is being developed through a collaboration with the French company Transgene. The company also markets DNA and siRNA transfection and labeling products.
Roche said that Mirus’ technology offers “an innovative way of getting RNAi therapeutics to specific disease targets,” which it said has been the “major challenge” of RNAi-based technologies.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.